Patients with prostate cancer are being recruited for participation in a research study involving Muscadine supplements

IRB/UVA Tracking #
21302
Principal Investigator
Robert Dreicer
Contact
Julio Torres III
Contact Phone
434.982.4110
Official Trial Title
The MAP TRIAL: PHASE III STUDY OF MUSCADINE PLUS (MPX) IN MEN WITH PROSTATE CANCER: A RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFECTS OF MPX CAPSULES ON RISING PROSTATE-SPECIFIC ANTIGEN LEVELS IN ALANINE/ALANINE SOD2 GENOTYPE MEN FOLLOWIN
Study Description

The University of Virginia Cancer Center is conducting a clinical research study for adults ages 18 and over who have prostate cancer, a rising PSA level after treatment and have specific genotype called Manganese SuperOxide Dismutase Gene (MSOD A/A gene.) The purpose of this study is to find out if Muscadine supplements can slow down the growth rate of prostate cancer in patients with the MSOD gene.

Initially, participation may last up to 11 months, however, it may be extended for up to an additional year depending on how patients respond to treatment. Study specific tests will be provided at no cost to you.

Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT03535675

Compensation

NA